Scott Ghostone Email & Phone Number

Bartlett, Il, Us

Chicago Region

ASTRAZENECA PHARMACEUTICALS, Gaithersburg, MDA British-Swedish multinational pharmaceutical and bio pharmaceutical company that specializes primarily in Oncology drugs; $45.8 billion in revenue, 89,900 employees worldwideExecutive Oncology Business Manager – Great Lakes District 2023 – PresentLeading a matrix organization of 7 Oncology Account Specialist launching and promoting AstraZeneca’s Breast Cancer portfolio (which includes a kinase inhibitor that targets PIK3CA and AKT for HR+/Her2- Metastatic breast cancer (Truqap), an antibody-drug-conjugate for HER2+ Metatstatic breast cancer {Enhertu} and a PARP Inhibitor for BRAC1 mutating Breast Cancer (Lynparza). Key accounts covered during my tenure include the Northwestern, Univ of Chicago, Mayo, Advocate/Aurora, Sanford, City of Hope (CTCA), Univ of Wisconsin, Froedtert, Fairview, etc). Reporting to the Oncology Area Director.Accomplishments• Successfully Launched Enhertu and currently ranked #2 Nationally out of 16• Current successful launch of Truqup with 105% growth over the 1st Quarter 2024• Successfully Implemented Geo-Tumor cadences to improve cross-departmental collaboration that led to consecutive Circle of Excellence Team wins 2021 and 2022 • Appointed to the faculty of AstraZeneca’s Emerging Leaders Leader’s program that led the promotion of 5 Oncology Specialist to Oncology Business Manager positions during recent expansions

Great Plains Region

Oncology Business Manager – Great Lakes District 2019 – 2023Leading a matrix organization of 9 Oncology Account Specialist promoting AstraZeneca’s Breast Cancer portfolio (which includes an antibody-drug-conjugate for HER2+ Metatstatic breast cancer {Enhertu} and a PARP Inhibitor for BRAC 1 mutating Breast Cancer. Key accounts include the Northwestern, Mayo Clinic, Cancer Treatment Center of America, Washington University, CCK, and the University of Kansas. Reporting to the Oncology Area Director.Accomplishments• Successfully Launched Enhertu in 2019 which included the Nation's #1 Account (Wash U.)• Responsible for building AZs new GU/GI sales team to launch current and new indications for Imfinzi (PD-L1) and Lymparza (PARP Inhibitor). Leading a team of 9 Oncology Professional Sales Specialist.• Business averaging double-digit growth with the Breast Cancer portfolio since launch though the pandemic by utilizing Business Improvement Principles.

Greatlakes Region

TEVA PHARMACEUTICAL, Frazier, PAAn Israeli multinational pharmaceutical company that specializes primarily in generic drugs; $20.3 billion in revenue, 43,000 employees worldwide Regional Sales Manager – Oncology/Greatlakes RegionResponsible for increasing sales of a $105 Million dollar portfolio in a $800 Million dollar total market. Leading a matrix organization of 9 Oncology Account Specialist promoting Teva’s Hematology portfolio (which includes an alkalying agent for CLL and iNHL and a G-CSF supportive care agent for febrile Neutropenia) and resources to Oncology, Pharmacy Directors and medical C-Suite personnel. Key accounts include the Cleveland Clinic foundation, University of Michigan, McClaren Health System, and Ohio State University. Reporting to the Area Sales Director.Accomplishments:• Currently leading the #1 Ranked Region nationally at Teva Oncology (2019) by developing a strategy that enabled the region defend the bendamustine franchise from new hematology competitive erosion• Leading Teva’s top region to a 96% Bendeka conversion rate from Treanda in 2017 that led to 118% Quota achievement and the #1 ranking for President’s Club and the National Region of the Year Award• Achieved Bendeka and Granix G-CSF contract wins at a number of key institutions including the Northwestern, University of Michigan, Ohio State, and Marietta Health Systems that lead to 20% YOY growth and Quota achievement of +110% for 2017• Implemented Business Improvement principles that lead to greater collaboration between the Sales, Marketing, and Market Access teams• Introduced to Teva leadership a new contracting strategy that lead to 6% business unit sales growth in Granix over the previous year.

Glenview, Illinois

Responsible for increasing sales of a $27 Million dollar ITW portfolio in the MRO Channel by creating and implementing strategies to increase Revenue and POS growth while increasing variable margin. Product growth primary segment focus include: Concrete Anchoring, Overhead, Adhesives, and Steel. Leading a matrix organization of 2 National Account Managers and 25 Territory Managers promoting ITW portfolio and resources to C-Suite, Regional Vice Presidents, and District Sales Managers of 8 National Accounts which include W.W. Grainger, Fastenal, and Ferguson. Reporting to the National Sales Director.Accomplishments:•Negotiated ITWs 1st Long-Term Contract with the business unit’s #1 National Account that lead to 1st Semester 2016 Quota achievement of +124%•Achieved 174% of Sales Quota 1st Year as National Sales Manager through the Strategic Account Planning process•Implemented Business Improvement principles that lead to synergies and accountability between the Sales and Marketing teams•Increased portfolio Variable Margin 17% over the previous year by implementing targeted strategies around the highest margin growth segments